The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

在涉及407名不可切除或转移性黑色素瘤患者的关键第3期试验中，联合疗法实现的中位无进展生存期为19.4个月，而pembrolizumab单药治疗为11.0个月 (HR=0.77，p=0.056)。

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

These data provide a robust rationale for this phase 3 trial of DV plus pembrolizumab in the 1L setting for HER2-expressing la/mUC. Methods: DV-001 (NCT05911295) is an open-label, randomized, ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Knocking down EPIC1 sensitized triple negative breast tumor-bearing mice to immunotherapy with the PD-1 inhibitor pembrolizumab.

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

Pembrolizumab–chemotherapy prolonged PFS compared with placebo–chemotherapy in the PD-L1 CPS ≥1, all-comer, and CPS ≥10 populations (Table 2 and Data Supplement). In all populations, the percentage of ...